– UK, Cambridge – Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, announced the appointment of Dr. Alex Dickinson to its Board of Directors as a Non-Executive Director.
About Dr. Alex Dickinson
Dr. Alex Dickinson is a seasoned executive bringing substantial experience from the intersection of healthcare, life sciences, and information technology to Sphere Fluidics’ leadership team. He joins the Board as part of a series of significant senior appointments to drive forward the Company’s global commercial expansion strategy, leveraging Alex’s extensive entrepreneurial and technical expertise to augment increased R&D efforts in areas of cutting-edge technological advancement.
From 2010 to 2017, Alex was SVP of Strategic Initiatives at Illumina, during which time revenues increased from £1 billion to £3 billion. In this position, he founded and led development of the cloud-based BaseSpace platform, which remains the Company’s core bioinformatics offering, and ran its global population sequencing healthcare programs. Alex joined Illumina through the acquisition of Helixis, which he co-founded with Nobel laureate David Baltimore and led as CEO. He was also the Founder and CEO of Luxtera, a leading supercomputer chip company acquired by Cisco Systems in 2019.
In addition to his new role at Sphere Fluidics, Alex is currently a Board Member of Gencove, pioneers of low-pass whole genome sequencing imputation and analysis, Co-Founder and Board Member of ChromaCode, innovators in genomics multiplexing technology, and Co-Founder and Chairman of Ryght.ai, healthcare technology developers leveraging generative AI and optimizing large language models (LLMs) to maximize productivity in biopharma discovery and clinical trials. Previously, he was a Board Member at NASDAQ-listed Clinical Research Organization, PRA Health Sciences, until its acquisition by ICON plc in 2021.
Dr. Alex Dickinson said: “What really excites me about joining Sphere Fluidics is the talent across the team and the capabilities of its microfluidic technology, with many cutting-edge developments already in the pipeline. Having worked closely with Dale at Illumina and Helixis, I am looking forward to joining him again to drive success at this pivotal stage in the Company’s development. There is a wealth of opportunities being created around the combination of life science technologies and emerging AI and machine-learning tools, such as LLMs. As one aspect of my new role, I am keen to explore how we can leverage these pioneering techniques alongside the platforms’ proven capabilities in data generation and analysis, opening new avenues for innovation and product development that are transformative for customers’ workflows.”
For more information : https://spherefluidics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.